Edwards Lifesciences Corp (NYSE: EW) has a price-to-earnings ratio of 25.67x that is above its average ratio. Additionally, the 36-month beta value for EW is 1.16. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 7 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for EW is 592.96M and currently, short sellers hold a 1.30% ratio of that float. The average trading volume of EW on July 29, 2024 was 3.53M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
EW) stock’s latest price update
Edwards Lifesciences Corp (NYSE: EW) has seen a rise in its stock price by 4.47 in relation to its previous close of 59.70. However, the company has experienced a -27.90% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2024-07-26 that Edwards Lifesciences cut TAVR guidance, stock price dropped by over 31%. Recent acquisitions and divestiture of the Critical Care business show strategic focus on the structural heart market. Analyst reiterates ‘Strong Buy’ rating with a fair value of $72 per share, confident in long-term growth potential.
EW’s Market Performance
Edwards Lifesciences Corp (EW) has seen a -27.90% fall in stock performance for the week, with a -31.88% decline in the past month and a -29.13% plunge in the past quarter. The volatility ratio for the week is 5.31%, and the volatility levels for the past 30 days are at 3.03% for EW. The simple moving average for the last 20 days is -29.61% for EW stock, with a simple moving average of -23.55% for the last 200 days.
Analysts’ Opinion of EW
Many brokerage firms have already submitted their reports for EW stocks, with Truist repeating the rating for EW by listing it as a “Hold.” The predicted price for EW in the upcoming period, according to Truist is $82 based on the research report published on July 25, 2024 of the current year 2024.
TD Cowen, on the other hand, stated in their research note that they expect to see EW reach a price target of $70, previously predicting the price at $100. The rating they have provided for EW stocks is “Hold” according to the report published on July 25th, 2024.
Robert W. Baird gave a rating of “Neutral” to EW, setting the target price at $70 in the report published on July 25th of the current year.
EW Trading at -29.52% from the 50-Day Moving Average
After a stumble in the market that brought EW to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.11% of loss for the given period.
Volatility was left at 3.03%, however, over the last 30 days, the volatility rate increased by 5.31%, as shares sank -33.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.86% lower at present.
During the last 5 trading sessions, EW fell by -27.90%, which changed the moving average for the period of 200-days by -14.44% in comparison to the 20-day moving average, which settled at $87.06. In addition, Edwards Lifesciences Corp saw -18.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EW starting from Lippis Daniel J., who sale 500 shares at the price of $94.18 back on Jul 11 ’24. After this action, Lippis Daniel J. now owns 23,189 shares of Edwards Lifesciences Corp, valued at $47,090 using the latest closing price.
BOBO DONALD E JR, the CVP,Strategy/Corp Development of Edwards Lifesciences Corp, sale 5,000 shares at $93.29 during a trade that took place back on Jul 10 ’24, which means that BOBO DONALD E JR is holding 46,936 shares at $466,474 based on the most recent closing price.
Stock Fundamentals for EW
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.77 for the gross margin
The net margin for Edwards Lifesciences Corp stands at 0.25. The total capital return value is set at 0.18. Equity return is now at value 21.35, with 15.44 for asset returns.
Based on Edwards Lifesciences Corp (EW), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 1.4. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is 58.76.
Currently, EBITDA for the company is 1.95 billion with net debt to EBITDA at -0.56. When we switch over and look at the enterprise to sales, we see a ratio of 6.11. The receivables turnover for the company is 7.19for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.71.
Conclusion
In conclusion, Edwards Lifesciences Corp (EW) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
